Pillar Biosciences Revenue and Competitors
Estimated Revenue & Valuation
- Pillar Biosciences's estimated annual revenue is currently $15.2M per year.
- Pillar Biosciences received $18.0M in venture funding in May 2016.
- Pillar Biosciences's estimated revenue per employee is $155,000
- Pillar Biosciences's total funding is $65.9M.
Employee Data
- Pillar Biosciences has 98 Employees.
- Pillar Biosciences grew their employee count by -17% last year.
Pillar Biosciences's People
Name | Title | Email/Phone |
---|
Pillar Biosciences Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Pillar Biosciences?
Pillar Biosciences aims to "Make Precision Medicine Accessible" by developing and manufacturing targeted next-generation sequencing (NGS)-based assays and software for today's high-throughput specialty NGS laboratories. Through our SLIMamp technology (a multiplex overlapping PCR chemistry) Pillar offers a streamlined, robust and economical workflow with high mapping and on-target metrics. In conjunction with the SLIMamp assay technology, Pillar Biosciences has an informatics pipeline called the Pillar Variant Analysis Toolkit (PiVAT) that is not only highly accurate, enabling somatic variant calls down to 1% allele frequency without use of Unique Identifiers (UIDs), but also fast and efficient, returning valuable sample data quickly. For higher-sensitivity applications such as cell-free DNA analyses, Pillar Biosciences has developed a dedicated assay technology for cell-free DNA that uses UID methodology, to work with the PiVAT pipeline to drive sensitivity down to 0.1%-0.2%.
keywords:Biotechnology,Healthcare,Medical Diagnostics,Pharmaceuticals$65.9M
Total Funding
98
Number of Employees
$15.2M
Revenue (est)
-17%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Pillar Biosciences News
... Exact Sciences/Thrive, Grail, Guardant, IV BioHoldings (IVBH), Natera, Pillar Biosciences and StageZero Life Sciences.
Pillar Biosciences is a global oncology solutions company delivering in-vitro diagnostics (IVD) that provide accurate, robust, timely,...
Pillar Biosciences is a global oncology solutions company delivering in-vitro diagnostics (IVD) that provide accurate, robust, timely,...
Pillar Biosciences, a Natick, Mass.- and Shanghai, China-based NGS clinical cancer diagnostics company, closed a $29.7m Series C financing. The round was led by ORI Healthcare Fund. The company intends to use the funds to accelerate the expansion of in vitro diagnostic and research use only pa ...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $15M | 100 | 11% | N/A |
#2 | $23.4M | 103 | 7% | N/A |
#3 | $24.3M | 107 | 2% | N/A |
#4 | $25M | 119 | 0% | N/A |
#5 | $12.3M | 123 | 22% | N/A |
Pillar Biosciences Funding
Date | Amount | Round | Lead Investors | Reference |
---|---|---|---|---|
2016-05-12 | $18.0M | Undisclosed | ORI Healthcare Fund L.P | Article |